SCHEMBL634516

SCHEMBL634516

CC(C)(C)OC(=O)N1CCC(Cc2nc(O)cs2)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.46
KDM4E B2RXH2 2/20 0.43
EED O75530 1/20 0.43
RBBP4 Q09028 1/20 0.43
SUZ12 Q15022 1/20 0.43
EZH2 Q15910 1/20 0.43
AEBP2 Q6ZN18 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.42
GLS O94925 4/20 0.42
USP30 Q70CQ3 2/20 0.42
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
FAAH O00519 1/20 0.41
GPR119 Q8TDV5 3/20 0.41
FEN1 P39748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14481602 0.93 GLS (0.49) PIK3CDEEDRBBP4SUZ12EZH2
SCHEMBL38665790 0.80 EED (0.46) KDM4EEEDRBBP4SUZ12EZH2
SCHEMBL20281805 0.77 PIK3CD (0.46) PIK3CDKDM4EMAPTPKMIDO1
SCHEMBL21603175 0.76 PIK3CD (0.47) PIK3CDKDM4EMAPTPKMUSP30
SCHEMBL21603190 0.76 PIK3CD (0.47) PIK3CDKDM4EMAPTPKMUSP30
SCHEMBL20281825 0.76 PIK3CD (0.47) PIK3CDKDM4EMAPTPKMUSP30
SCHEMBL23791421 0.76 GPR119 (0.55) PIK3CDKDM4EPKMUSP30IDO1
SCHEMBL30779407 0.76 GPR119 (0.45) PIK3CDKDM4EPKMGLSUSP30
SCHEMBL30779406 0.76 GPR119 (0.45) PIK3CDKDM4EPKMGLSUSP30
SCHEMBL30779497 0.76 GPR119 (0.45) PIK3CDKDM4EPKMGLSUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419405-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS Theravance, Inc. (US) 2012-02-22 EP disclosed
WO-2010120910-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS THERAVANCE, INC. (US) 2010-10-21 WO disclosed
US-20100267743-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267743-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS HTR3C, SLC6A2, ADRB3 PIK3CD 1070/4885KDM4E 631/4885EED 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.